Comparative Pharmacology
Head-to-head clinical analysis: QUINAGLUTE versus QUINIDINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINAGLUTE versus QUINIDINE SULFATE.
QUINAGLUTE vs QUINIDINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; binds to sodium channels and inhibits the fast inward sodium current, slowing phase 0 depolarization and prolonging the action potential duration. Also exhibits anticholinergic and negative inotropic effects.
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction. It also inhibits potassium channels, prolonging repolarization, and has vagolytic and negative inotropic effects.
324-648 mg orally every 8-12 hours; extended-release formulation (quinidine gluconate).
300-600 mg orally every 6-8 hours; maximum 2-4 g/day. Extended-release: 300-600 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours in adults with normal renal function. In hepatic impairment, half-life may increase to 12-24 hours; in severe renal impairment (CrCl <10 mL/min), half-life may exceed 24 hours.
Terminal elimination half-life is 6-8 hours in healthy adults; prolonged to 12-18 hours in heart failure, hepatic cirrhosis, or severe renal impairment (CrCl < 10 mL/min).
Renal elimination of unchanged drug and metabolites accounts for approximately 60-70% of total clearance. Biliary/fecal excretion contributes about 20-30%. Acidic urine increases renal clearance.
Renal excretion of unchanged drug accounts for 10-20% of elimination; hepatic metabolism (hydroxylation and N-oxidation) accounts for 70-80%; about 5% excreted in feces via biliary elimination.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)